{"filing":{"accession_number":"0001628280-26-044618","cik":"0001737287","ticker":"ALLO","company_name":"Allogene Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-22","report_date":null,"primary_document":"allo-20260618.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1737287/000162828026044618/allo-20260618.htm"},"events":[{"id":12739,"run_id":11302,"accession_number":"0001628280-26-044618","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"Allogene held its 2026 Annual Meeting of Stockholders on June 18, 2026, with final voting results reported for five proposals: election of three Class II directors (Messemer, Sato, Witte), advisory approval of named executive officer compensation, say-on-pay frequency (approved annually), amendment to increase authorized shares from 400 million to 800 million, and ratification of Ernst \u0026 Young LLP as independent auditor.","company_name":"Allogene Therapeutics, Inc.","ticker":"ALLO","filing_date":"2026-06-22","form":"8-K","submitted_at":null,"items":[{"id":9674,"accession_number":"0001628280-26-044618","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 disclosure reports the results of Allogene's 2026 Annual Meeting of Stockholders held on June 18, 2026, covering five proposals: election of three Class II directors (Messemer, Sato, Witte), advisory approval of named executive officer compensation, say-on-pay frequency (approved annually), amendment to increase authorized shares from 400M to 800M, and ratification of Ernst \u0026 Young LLP as independent auditor. The filing presents final voting tallies for each proposal, making this a textbook shareholder vote results disclosure under Item 5.07.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-22T20:48:31.451109+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":12740,"run_id":11302,"accession_number":"0001628280-26-044618","anchor_item_number":"8.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"summary":"Allogene filed a prospectus supplement on June 22, 2026 authorizing sales of up to $135.0 million in common stock pursuant to an at-the-market (ATM) sales agreement with TD Securities, representing a material dilutive equity issuance.","company_name":"Allogene Therapeutics, Inc.","ticker":"ALLO","filing_date":"2026-06-22","form":"8-K","submitted_at":null,"items":[{"id":9675,"accession_number":"0001628280-26-044618","item_number":"8.01","item_title":"Other Events.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"The Company filed a prospectus supplement on June 22, 2026 authorizing sales of up to $135.0 million in common stock pursuant to an ATM (at-the-market) Sales Agreement with TD Securities. This is a dilutive equity issuance that would materially affect shareholder ownership and is a strong signal of capital-raising activity typical of smaller biotech firms like Allogene.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-22T20:48:31.451109+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":9674,"accession_number":"0001628280-26-044618","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 disclosure reports the results of Allogene's 2026 Annual Meeting of Stockholders held on June 18, 2026, covering five proposals: election of three Class II directors (Messemer, Sato, Witte), advisory approval of named executive officer compensation, say-on-pay frequency (approved annually), amendment to increase authorized shares from 400M to 800M, and ratification of Ernst \u0026 Young LLP as independent auditor. The filing presents final voting tallies for each proposal, making this a textbook shareholder vote results disclosure under Item 5.07.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-22T20:48:31.451109+00:00","company_name":"Allogene Therapeutics, Inc.","ticker":"ALLO","filing_date":"2026-06-22"},{"id":9675,"accession_number":"0001628280-26-044618","item_number":"8.01","item_title":"Other Events.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"The Company filed a prospectus supplement on June 22, 2026 authorizing sales of up to $135.0 million in common stock pursuant to an ATM (at-the-market) Sales Agreement with TD Securities. This is a dilutive equity issuance that would materially affect shareholder ownership and is a strong signal of capital-raising activity typical of smaller biotech firms like Allogene.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-22T20:48:31.451109+00:00","company_name":"Allogene Therapeutics, Inc.","ticker":"ALLO","filing_date":"2026-06-22"}]}